Abstract: The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and for determining specific serotonin reuptake inhibitor (SSRIi) activity for treatment of depression. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I-A, Formulae II-A, Formula II-D, or Formula III-A, or a pharmaceutically acceptable salt thereof.

Abstract: The one subject of the invention is the compounds of general formula (I), their isomers, their physiologically acceptable salts and/or Mn(II), Fe(II), Fe(III), Co(II) and Ni(II) complexes. The other subject of the invention is the application of the above compounds.

Abstract: An electron beam irradiation device which can uniformly project electron beams to the entire outer surface of a container by using a small-sized low-energy electron accelerator. When each of the side surface portions of the container is irradiated with the electron beams by supporting a bottom surface portion of the container, a position of the container is moved by the supporting portion so that a distance between each of the side surface portions of the container and an irradiation window of the electron accelerator is made substantially equal. Subsequently, when an upper surface portion and a bottom surface portion of the container are irradiated with the electron beams by holding the side surface portion of the container, the position of the container is moved by the holding portion so that the distances between the upper surface portion and the bottom surface portion of the container and the irradiation windows of the electron accelerators become substantially equal.

Abstract: A device for increased ultraviolet exposure of fluids. The device includes at least one photonic source for generating and emitting photonic energy in a wavelength or in a range of wavelengths of visible light. The device also includes a lens formed of a fluoropolymer material wherein the at least one photonic source is sealed within an interior and underneath an outer surface of the fluoropolymer material so as to be surrounded by the fluoropolymer material. The at least one photonic source is coupled with the lens such that the photonic energy emitting from the at least one photonic source transmits through and projects beyond the fluoropolymer material. The lens propagates photons in an omnidirectional pattern simultaneously throughout the entirety of the lens. The joining of the at least one photonic source and the fluoropolymer material comprises all components for generating and emitting photonic energy when the photonic source is activated, such that it is an operable source.

Abstract: A device for rapidly sanitizing a surface is described. The device has an enclosure having an opening adapted to insert a surface, and an interior; a liquid nitric oxide solution applicator; and an absorbent material. The liquid nitric oxide solution applicator is in fluid communication with the interior of the enclosure and is adapted to apply liquid nitric oxide solution onto the surface when the surface is positioned within the enclosure. A method of rapidly sanitizing a surface is described. The devices and methods provided herein may be implemented to sanitize the surface of any body part or item that may be placed within the device. An infectious agent on the surface may be killed; i.e., the surface is disinfected. Non-limiting applications of the devices and methods include preventing nosocomial infections or food contamination, sanitizing household items, and implementing sanitizing procedures to comply with FDA Good Manufacturing Practices.

Abstract: An automatic cleaning device includes an accelerometer, a sprayer, a driving module and a processing unit. The accelerometer is mounted to a door, measures acceleration of the door, and outputs an acceleration value accordingly. The sprayer is for storing cleaner, and is operable to spray the cleaner. The processing unit is electrically connected to the driving module and the accelerometer, and determines whether the acceleration value is greater than an acceleration threshold, and generates a driving signal and transmits the same to the driving module for enabling the driving module to drive the sprayer to spray the cleaner when determining that the acceleration value is greater than the acceleration threshold.

Abstract: A device for generating and dispersing chlorine dioxide which includes a housing, at least one removeable tray having a plurality of compartments contained within an interior of the housing, and a fan in communication with the interior of the housing and the exterior of the housing for directing a current of chlorine dioxide gas that is generated from chemicals that are positioned within the removeable tray(s).

Abstract: There are provided a treatment tank generating a gas phase around a rotating center of a rotating flow of a liquid by rotating the introduced liquid, a first electrode whose at least a part is disposed in the treatment tank and in contact with a liquid in the treatment tank, a second electrode disposed so as to be in contact with the liquid in the treatment tank, and a power source applying a voltage between the first electrode and the second electrode to generate plasma in a gas phase, the plasma is generated in the gas phase to generate modification components, the generated modification components are dissolved and dispersed in the liquid, and a modification liquid is generated and retained in the storage tank. The modification liquid is sprayed or scattered from a nozzle into a treatment target space via a supply pump in the form of mist.

Abstract: A photo catalytic filter is configured such that a plurality of plate-shaped members on which a photocatalyst is carried face each other with a gap therebetween, and the gaps form an air flow path. Each plate-shaped member has end surfaces respectively on an air entrance side and an air exit side of the gap. A UV irradiation unit faces the end surfaces on at least one of the air entrance side and the air exit side of the plate-shaped members, and is a predetermined distance away from those end surfaces. An air supply path for taking air from a lateral direction substantially parallel to the end surfaces, and supplying the air to the flow path, or an air discharge path for discharging the air exiting the flow path to a lateral direction substantially parallel to the end surfaces, is formed between the UV irradiation unit and the end surfaces of the plate-shaped members.

Abstract: The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers. Upon exposure to a liquid the electrospun fibers dissolve immediately and the substances of interest are released into the liquid. Exemplary devices include bandages formed from electrospun dextran fibers and associated agents that promote hemostasis, such as thrombin and fibrinogen.

Abstract: A method of repairing a partial or complete ACL tear using a biologically active suture combined with a suture anchor. The biologically active material may be an angiogenic material that provides a biological stimulus (such as blood vessel growth) to initiate the repair cascade throughout the tear.

Abstract: The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for tamponade hemostasis of bone or cartilage.

Abstract: Embodiments of the disclosure relate to implantable objects and guiding devices, as well as recipient site preparation instruments, bone-implantable materials, and methods of fabrication and use thereof.

Abstract: A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection.

Abstract: Provided are a hyaluronic acid composition having excellent viscoelasticity and being easily injectable, and a preparation method thereof.

Abstract: A collagen-coated tissue based membrane that is smooth on both sides so as to inhibit cell and tissue adhesion. Also disclosed are methods for making a collagen-coated tissue-based membrane.

Abstract: Provided herein are settable and non-settable compositions for use in surgical procedures comprising a variety of disclosed particles and optionally including previously unclotted, lyophilized, optionally crosslinked mammalian blood plasma. Also provided are related compositions, including surgical kits and packages, as well as methods of making and using the compositions.

Abstract: Disclosed are methods of enhancing regeneration of the nucleus pulposus through enhancement of perispinal perfusion in combination with a regenerative intervention. In one embodiment the invention teaches stimulation of enhancement of perispinal perfusion by administration of angiogenic agents prior to performing a regenerative intervention such as administration of a stem cell therapy. In one specific embodiment perispinal angiogenesis is stimulated by administration of autologous bone marrow mononuclear cells in the perispinal area, preferably into a muscular area, subsequent to which intradiscal administration of regenerative cells, such as mesenchymal stem cells is performed.

Abstract: Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells and optionally a hydrogel. In some embodiments, administering the cells promotes repair and regeneration of degenerated IVD tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

Abstract: The invention disclosed herein generally relates to methods and systems for growing, expanding and/or obtaining 3-dimensional lung-like epithelium comprising cells having SOX9 protein activity and SOX2+ protein activity. In particular, the invention disclosed herein relates to methods and systems for growing human cells having SOX9 protein activity and SOX2+ protein activity in vitro, and for promoting pluripotent stem cell derived ventral-anterior foregut spheroid tissue into 3-dimensional lung-like epithelium comprising cells having SOX9 protein activity and SOX2+ protein activity.

Abstract: The invention relates to resorbable crosslinked form stable membrane which comprises a composite layer of collagen material and inorganic ceramic particles containing 1.5 to 3.5 weight parts of inorganic ceramic for 1 weight part of collagen material, sandwiched between two layers of elastic pretensed collagen material (collagen material that has been stretched such as to be in the linear/elastic region of the stress-strain curve), the collagen material comprising 50-100% (w/w) collagen and 0-50% (w/w) elastin, and has shape and dimensions suitable for use in human tissue regeneration outside the oral cavity in rhinoplasty, postlateral spinal fusion or orbital reconstruction.

Abstract: A tetracycline salt comprising a tetracycline and an organic acid wherein the organic acid is oxalic acid or maleic acid is provided. The tetracycline is preferably doxycycline, minocycline, sancycline, lymecycline, tetracycline or demeclocycline, and preferred salts include oxycycline maleate, minocycline oxalate, tetracycline oxalate, demeclocycline maleate, demeclocycline oxalate, sancycline maleate, lymecycline maleate, or lymecycline oxalate. A pharmaceutical formulation comprising a tetracycline salt according to the invention is also provided, as is a medical device having coated thereon a salt or pharmaceutical formulation according to the invention. A salt of the invention, or a formulation of the invention are also provided for use as medicaments, particularly for use in the treatment or prevention of an inflammation and/or an infection.

Abstract: Implantable materials having defined patterns of affinity regions for binding endothelial cells and providing for directed endothelial cell migration across the surface of the material. The affinity regions include photochemically altered regions of a material surface and physical members patterned on the material surface that exhibit a greater affinity for endothelial cell binding and migration than the remaining regions of the material surface.

Abstract: The disclosure provides drug delivery devices and methods of making and using the drug delivery devices. The devices include single and multi-layer polymer films made by a breath figure technique having therapeutic agents associated therewith. For example, the devices may be a dual layer polymer film wherein the first layer includes a therapeutic agent incorporated into it by spin coating the first agent with a polymer solution and the second agent is incorporated into the second layer by loading the agent into pores of the second layer after it is spin coated onto the first layer. In some cases one layer provides a burst release and the second layer provides a slow release drug delivery profile. The devices may take on the form of a surgical mesh with a slow release therapeutic drug.

Abstract: An antithrombogenic metallic material includes a metallic material whose surface is coated with a coating material, the coating material containing: a phosphonic acid derivative or a catechol derivative; a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; the polymer being covalently bound to the phosphonic acid derivative or the catechol derivative, the phosphonic acid derivative or the catechol derivative being bound to the metallic material through a phosphonic acid group or a catechol group thereof, wherein the abundance ratio of nitrogen atoms to the abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on the surface is 4.0 to 13.0 atomic percent.

Abstract: There is provided a colon cleaning device comprising: a tube through which liquid and fecal matter are removed from a colon of a patient, the tube having a longitudinal axis; a cleaning head positioned at the distal end of the tube, the cleaning head having at least one opening coaxial with the longitudinal axis, the at least one opening sized for fecal matter to enter the interior of the cleaning head from the colon; at least one disassembly element disposed within the cleaning head; and an actuating mechanism which actuates the disassembly element to perform sweeping displacement inside the cleaning head so that the at least one disassembly element rotates around the longitudinal axis to slice through the fecal matter; wherein the cleaning head and the tube are sized and shaped to be displaced along the colon of a patient.

Abstract: A low-cost and simple-to-use system and method to facilitate a prophylactic pleural lavage protocol at the time of thoracostomy tube placement for traumatic hemothorax in order to reduce the need for secondary intervention for the management of retained hemothorax. The invention may be used in conjunction with existing chest tubes and be administered at the time of initial chest tube placement, and continued at the bedside (by a bedside nurse) over the duration of chest drainage, as necessary. The system includes an operator device that semi-automatically administers a pleural lavage protocol consisting of saline instillation, and suction to slow the clotting process, prevent “gelling” of blood, and maintain drainability.

Abstract: A surgical hand piece has a source of ultrasonic energy provided to a connecting body having a first passage with one end to receive fluid from a first source and the other end at the connecting body distal end. A work tip has first and second tubes each having at least one opening at its distal end and the proximal end of one or both of the tubes connected to the connecting body distal end to receive the ultrasonic energy and to selectively receive or discharge fluid from either the first or second source as controlled by a valve. A cannula is provided which is adapted to be placed in an opening in the cornea through which the work tip extends during the removal of cataracts from the eye by phacoemulsification. The cannula may be equipped with channels that permit additional infusion of fluid into the eye during the procedure, which infusion also cools the surrounding corneal tissue to protect against heat generated by the ultrasonic vibration of the work tip.

Abstract: A method for collecting plasma includes determining the weight and hematocrit of a donor, and inserting a venous-access device into the donor. The method then withdraws blood from the donor through a draw line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate (1) a percentage of anticoagulant in the collected plasma component, and (2) a volume of pure plasma collected within the plasma collection container. The volume of pure plasma may be based, at least in part, on the calculated percentage of anticoagulant. The method may continue until a target volume of pure plasma is collected within the plasma collection container.

Abstract: A catheter pump assembly is provided that includes a proximal a distal portion, a catheter body, an impeller, and a flow modifying structure. The catheter body has a lumen that extends along a longitudinal axis between the proximal and distal portions. The impeller is disposed at the distal portion. The impeller includes a blade with a trailing edge. The flow modifying structure is disposed downstream of the impeller. The flow modifying structure has a plurality of blades having a leading edge substantially parallel to and in close proximity to the trailing edge of the blade of the impeller and an expanse extending downstream from the leading edge. In some embodiments, the expanse has a first region with higher curvature and a second region with lower curvature. The first region is between the leading edge and the second region.

Abstract: A control system in a blood line (12) of a cardiopulmonary bypass perfusion system (1) comprises a flow sensor (26) to determine a flow value indicative of the flow rate, a controller configured to process the flow value, and an adjustable restriction (28) responsive to the controller, to reduce the flow rate in the venous blood line (12) to maintain a flow rate to the venous blood reservoir that does not exceed a restriction threshold. As the adjustable restriction (28) is responsive to the flow sensor (26), this provides a closed loop control mechanism that avoids restricting the blood line (12) of the perfusion system (1) more than intended.

Abstract: A dialysis device implantable in a patient for dialysis includes a filtration unit. The filtration unit includes at least one dialysis chamber for containing and/or circulating dialysate; and at least one blood chamber for containing and/or circulating blood of the patient, disposed on at least one dialysis chamber and being in communication with the at least one dialysis chamber. Each of the at least one dialysis chamber and the at least one blood chamber comprise at least one inlet for circulating fluid into and/or out of the at least one dialysis chamber and the at least one blood chamber. The at least one dialysis chamber and the at least one blood chamber are configured such that the blood in the at least one blood chamber and the dialysate in the at least one dialysis chamber operably interact with each other for dialysis.

Abstract: A wearable ultrafiltration apparatus is provided. The apparatus can include a first ultrafilter for filtering a patient's blood along a first fluid path and a second ultrafilter for filtering the patient's blood along a second fluid path. The apparatus can also include a valve being positionable in a first position for directing the patient's blood along the first fluid path. The valve can also be positioned in a second position for directing the patient's blood along the second fluid path. When the valve is in the first position, blood can flow along the first fluid path and prevent blood from flowing along the second fluid path. When the valve is in the second position, blood can flow along the second fluid path and prevent blood from flowing along the first fluid path. When the valve is in the first position, the second ultrafilter can be idle and capable of being serviced or replaced and when the valve is in the second position, the first ultrafilter can be idle and capable of being serviced or replaced.

Abstract: The invention relates to a dialysis machine capable of performing ultrafiltration without the need for a dedicated ultrafiltration pump. The system uses a pair of membrane flow balance pumps wherein the operation and/or the volume flow rate of the pumps can be modified during operation to bring about a net movement of dialysate either into or from the dialyser. The direction of flow of the dialysate in the dialyzer is reversible and the dialyzer can comprise two dialysate inlets, one at each end, and two dialysate outlets, one at each end.

Abstract: An assembly for adding a medication or like substance to a liquid solution in a flexible bag (10) is provided. The flexible bag (10) contains a liquid solution, such as dialysate. An adapter (14) extends from the flexible bag (10) and includes a skirt (20) having an array of resilient sections (22) for engaging and snapping onto a neck finish (106) of a separate vial (100) containing a medication or like substance. A locking device (16) is adapted to be secured about the skirt (20) in a locking position that prevents outward movement of the array of resilient sections (22) and thereby prevents disengagement of the vial (100) from the adapter (14). A method of transferring the liquid solution from the bag (10) to the vial (100), mixing the medication with the liquid solution, and returning the mixture to the bag (10) is also provided.

Abstract: A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.

Abstract: An exhaust gas flow control system for an oxygenator of an extracorporeal ventilation system connected to an oxygenation gas supply line and to an exhaust line for removal of exhaust gas comprises a flow control path, a pressure control path, an exhaust flow regulator responsive to the controller, and an exhaust gas pressure regulator responsive to a controller configured to maintain a pre-determined pressure level in the exhaust line. This provides a better degree of control over the pressure across the oxygenator from oxygenation gas inlet to exhaust.

Abstract: A clinical parameter calculation-simulation-monitoring system includes an interface configured to receive data input pertaining to one or more input parameters; a processor operably connected to receive data signals from the interface corresponding to the received data input pertaining to the one or more input parameters, wherein the processor calculates one or more output values based on the one or more input parameters, wherein the one or more output values pertain to clinically relevant outcome parameters; and a monitor display assembly operably connected to receive the one or more output values calculated by the processor, wherein the monitor display assembly includes a display configured for monitoring at least one of the one or more output values calculated by the processor.

Abstract: A blood processing system includes a centrifuge and an optical monitoring system mounted at a stationary radial position with respect to the centrifuge. A flow circuit may be mounted within the centrifuge, with an umbilicus of the flow circuit extending outside of the centrifuge. A midsection of the umbilicus is orbited around a rotational axis of the centrifuge at a uniform first speed, which causes the centrifuge to rotate at a non-uniform second speed that is approximately double the first speed. The monitoring system is configured to view the flow circuit through a radial window of the centrifuge to determine a characteristic of the flow circuit. The yoke and/or umbilicus may occasionally move into position between the monitoring system and the window, so a controller of the monitoring system is configured to determine when unobstructed light reflected through the window by the centrifuge is received by the monitoring system.

Abstract: A method for collecting plasma includes determining the weight, height, and hematocrit of a donor, and calculating a donor plasma volume and a target plasma collection volume. The target plasma collection volume is based on the donor plasma volume and a target percentage of plasma. The method then withdraws blood from the donor through a line connected to a blood component separation device, and introduces anticoagulant into the withdrawn blood. The blood component separation device separates the blood into a plasma component and a second blood component, and the plasma component is collected from the blood component separation device and into a plasma collection container. The method may then calculate the volume of pure plasma collected within the plasma collection container, and continue processing/collecting until the calculated volume of pure plasma equals the target plasma collection volume.

Abstract: Syringe assemblies comprising a first cap and a second cap to ensure sterilization of the fluid path without the need for external packaging are described. Also described are methods of sterilizing the fluid path of a syringe assembly.

Abstract: An IV line identification system to enable ready identification of an IV line and its associated fluid source and output and to enable distinguishing the IV line from other IV lines and their fluid sources and outputs. The IV line identification system includes a first light source and a second light source communicatively coupled to one another via a wireless connection. The light sources are configured such that when one is activated so as to generate a light signal, the other is automatically activated to generate a corresponding light signal. Each light source may be placed on opposite ends of an IV line to enable ready identification of each end of the same IV line.

Abstract: An intravenous (IV) set system comprising a primary IV set defining a primary flow line of the IV set system. The primary flow line can include multiple access points along its length and feeds to a merging fluid pathway proximate to the distal terminus of the primary IV set. At least one secondary IV set with corresponding flow lines can be separably joined to the primary IV set to cause the secondary flow lines to be in fluid communication with the primary flow line. At least one of the IV sets can have a unique set of uniform marking indicia to facilitate rapid identification of the IV sets from other IV sets within the IV set system. Such marked and identified primary and/or secondary IV sets can be allocated to specific medical functions and/or can be for use by specific medical personnel to thereby minimize risk of error in administration of an IV to a patient. The IV set system can further comprise a merging fluid pathway about a primary IV set.

Abstract: A pumping chamber (8) for a micro-pump (2), the pumping chamber having a volume of 100 micro litres or less bounded by an interior wall and having an inlet (87) and an outlet (88), wherein the interior wall has at least one inwardly projecting rib (70) having a first end adjacent the inlet and a second end adjacent the outlet.

Abstract: The present application relates to an infusion set (80). The infusion set (80) has a base (90) for mounting on a user, and a connector (100) which engages with the base (90) to form a flow path between the connector (100) and a cannula mountable on the base (90). The connector (100) is configured to be selectably mountable to the base (90) in at least two predetermined mounting orientations. The present application also relates to an infusion set base (90), an infusion set connector (100), an infusion set cannula, and a method of assembling an infusion set (80).

Abstract: Various embodiments may provide a drug delivery apparatus for coupling with a container. The drug delivery apparatus may include a fluid conduit, a sensor configured to determine the coupling of the container to the drug delivery apparatus, and a flow controller configured to switch between an open state which allows fluid flow through the fluid conduit to a subject, and a closed state which prevents fluid flow through the fluid conduit to the subject. The drug delivery apparatus may additionally include a communication module configured to communicate via wireless means with a remote drug identification apparatus, and a processing module electrically coupled to the communication module and to the flow controller.

Abstract: The present invention relates to a flowrate regulating device for a medical infusion set and, more specifically, to a flowrate regulating device for an infusion set, the device comprising: a body member formed in a cylindrical shape opened vertically, and having an inflow tube and a discharge tube, which protrude from both sides thereof; a rotating member rotatably coupled to the upper end of the body member, and having a plurality of flowrate regulating passages provided on the outer diametral surface thereof and connected to the inflow tube; a fixing member fixedly coupled to the lower end of the body member, and having a discharge passage provided on the upper surface thereof and connecting the lower ends of the flowrate regulating passages and the discharge tube; and an injection port unit selectively provided at the rotating member and/or the fixing member.

Abstract: An injection device comprises an injector body having at least one indicator aperture; a medicament reservoir disposed within the injector body; a piston; and one or more status indicators. A movement of the piston expels a medicament out of the medicament reservoir, and operates to move at least one of the one or more status indicators relative to a corresponding indicator aperture.

Abstract: An injection device with a feedback mechanism includes a housing for a medicament container having a stopper, a plunger rod for acting on the stopper, a button interactively connected to the plunger rod, an activation member having a flexible locking device releasably connected to the plunger rod, a drive force device, a locking member slidable between positions in which the locking member either completely or partially surrounds the flexible locking device, and a guide rod. Audible and tactile information that an injection has started is provided by the plunger rod's hitting the stopper.

Abstract: The present disclosure concerns a needleless injection device including a body forming a housing, a gas generator, a tubular reservoir which contains an active ingredient to be injected, and a generally T-shaped elastically deformable membrane. The membrane includes a tubular portion which extends axially in the reservoir and is designed to lie axially in the reservoir under the effect of the pressure generated by the gas generator. A nozzle for injecting the active ingredient is arranged at the lower end of the reservoir. The device further includes a sock which wraps the tubular portion of the membrane, at least partially. The sock is adapted to limit the friction between the tubular portion of the membrane and the reservoir.